Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Region Västmanland | OTHER |
| Uppsala University | OTHER |
| Centrallasarettet Västerås | OTHER |
| Uppsala University Hospital |
Not provided
Not provided
Not provided
Not provided
Summary
Reducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment. Therefore, the goal of this project is with a multicenter randomised controlled design investigate whether a digital support intervention during ongoing neo- or adjuvant cancer treatment for breast, prostate or colon cancer is effective in reducing sedentary lifestyle and improving well-being in the short and long term.
Description of the project
This project is about investigating the effect of a digital support intervention to reduce sedentary behavior in people with breast, prostate, or colorectal cancer during neo- or adjuvant cancer treatment. The digital support intervention has been developed with patients and researchers and consists of existing high-quality technology that provides support for setting and following goals. The people who use the digital support intervention also receive support from a physiotherapist to set goals for reduced sedentary time and get to choose which activities will replace the time spent sedentary.
The goal of the project
The goal of the project is to investigate the effects of a digital support intervention on reduced sedentary and well-being during ongoing cancer treatment, both in the short and long term. In addition, the project will study the health-economic effects, and climate benefits of using the digital support intervention. By focusing on reducing a sedentary lifestyle and replacing it with daily activities and/or physical activity, the health of individuals is expected to be positively affected in the short term through, for example, increased well-being and reduced side effects from cancer treatment, and the long term through a reduced risk of developing complications and new illness related to the cancer treatment, such as cardiovascular disease.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Participants receive a digital support intervention |
|
| Control | No Intervention | Control condition. Individuals receive the care as usual provided by the healthcare only. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Digital self-management program | Behavioral | The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| Sedentary behavior time | The Axivity accelerometer is used for measuring the primary outcome of sedentary time, i.e. mean time spent in sedentary behavior/day. | At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point. |
| Measure | Description | Time Frame |
|---|---|---|
| Sedentary behavior bouts | The Axivity accelerometer is used for measuring sedentary bouts, i.e. mean number of bouts/day and mean bouts time/day. | At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point. |
| Physical activity |
| Measure | Description | Time Frame |
|---|---|---|
| Demographic variables | Study specific questions | Baseline |
| Diagnoses | Data regarding cancer diagnose and if any, co-morbid conditions, are gathered from medical records or Swedish national quality registers. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Petra von Heideken Wågert, Professor | Contact | +46 (0)21-10 3188 | petra.heideken.wagert@mdu.se | |
| Anna Henriksson | Contact | anna.km.henriksson@uu.se |
| Name | Affiliation | Role |
|---|---|---|
| Petra von Heideken Wågert, Professor | Mälardalen University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Akademiska sjukhuset | Recruiting | Uppsala | Sweden | |||
| Västmanlands sjukhus |
Not provided
| Label | URL |
|---|---|
| Offical study web page at Mälardalens University | View source |
Not provided
Individual medical information may not be shared with other researchers if the research questions are not within the scope of the current approved Swedish Ethical Review Board application (and any amendments) for this research. Only pseudonymous information may be shared after approval has been provided from the Swedish Ethical Review Board.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D015179 | Colorectal Neoplasms |
| D011471 | Prostatic Neoplasms |
| D057185 | Sedentary Behavior |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| OTHER |
| Uppsala County Council, Sweden | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
|
The Axivity accelerometer is used for measuring physical activity mean time/day and mean time spent in low-, moderate and high intensity physical activity. |
| At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point. |
| Health-related quality of life | Patient reported health related quality of life will be assessed with European Organization for Research and Treatment of Cancer QLQ C 30 and diagnose specific modules BR23, PR26 and CR29. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Health-related quality of life | Patient reported health related quality of life will be assessed with EQ5D, and used for calculation of Quality Adjusted Life Years. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Cancer related fatigue | Patient reported outcome cancer related fatigue is measured with Brief Fatigue Inventory. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Fear of movement | Patient reported outcome Fear of movement is assessed with Cancer specific Tampa Scale for Kinesiophobia. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Changes in health | Patient reported outcome Changes in health is assessed with Patient Global Impression of Change Scale. | At 3-months, 6 months, 12 months and 24 months. |
| Work ability | Selected and adapted questions from Work Ability Index are used for assessing patient reported outcome work ability. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Self-efficacy for reducing sedentary behavior | Study specific question is used for assessing patient reported outcome of Self-efficacy for reducing sedentary behavior. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Perceived support from peers | Study specific question is used for assessing patient reported outcome of Perceived support from peers. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| At baseline |
| Cancer treatment | Data regarding planned and received oncological and surgical cancer treatment (type, dose, treatment start and end date of treatment) and any treatment related side-effects are gathered from medical records and Swedish quality registers. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Health care costs | Data regarding outpatient visits, hospitalization and prescribed medication is gathered from Swedish national quality registers. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Costs of intervention | Data regarding cost of application use and any cost for physical activity is gathered from study records and patient reported by study specific questions. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Sick leave | Data regarding sick leave, i.e. total number of days being on sick leave gathered from the Swedish insurance fund (data on sick leave more than 14 days) and patient reported study specific questions (data on sick leave less than 14 days). Data will be gathered from 6 months prior baseline (study specific questions are administered at baseline and register data will be gathered at baseline but will include any data 6 months prior baseline). | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Adherence | Adherence to the intervention is assessed by Axivity accelometer and patient reported study specific questions. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Green house gas emissions | Green house emissions will be compared between the intervention and control group and estimated using a life cycle analysis of the technology used in the intervention, self-reported changes in climate behavior, and emissions from healthcare. | At baseline, 3-months, 6 months, 12 months and 24 months. |
| Recruiting |
| Västerås |
| Sweden |
| D017437 |
| Skin and Connective Tissue Diseases |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D001519 | Behavior |